ABSTRACT
OBJECTIVE: The aim of the present study was to explore the relation between lung function and serum retinol (SR) in cystic fibrosis (CF) patients. METHODS: This was a cross-sectional study conducted in a group of 98 young patients with CF (6.8-22.3 years), after the exclusion of those with pulmonary exacerbation, vitamin A deficiency, or other risks, from an initial group of 124 cases. RESULTS: Data of forced expiratory volume in 1 second (FEV1) were widely scattered (87.7% ± 16.9%). These were similar in the 78 pancreatic insufficient and 11 pancreatic sufficient patients. SR (56.6 ± 18.4 µg/dL) was >2.5th percentile of healthy people in the whole group, although 31 patients were situated above the 97.5th percentile (higher value: 110 µg/dL). The FEV1 was noticeably higher in these than in those within the normal range (93.6 ± 14.0 vs 85.0 ± 17.6 µg/dL; P < 0.05). The z score of SR correlated positively with FEV1 (r = 0.364; P = 0.000), after adjusting data for sex, age, body mass index, and pancreatic function. The odds ratio for a FEV1 >80% is 3.78 in patients with SR above the 97.5th percentile, versus only 0.26 in those within the normal range. There were no cases with retinol toxicity. CONCLUSIONS: FEV1 of young patients with CF correlates positively with SR, regardless of age, pancreatic function, or nutritional condition. Those with a moderately high retinol (up to 110 µg/dL) maintain the best respiratory function (FEV1 ≥80% in >90% of them) without any signs of toxicity.
Subject(s)
Cystic Fibrosis/blood , Cystic Fibrosis/physiopathology , Lung/physiopathology , Up-Regulation , Vitamin A/blood , Adolescent , Adult , Antioxidants/adverse effects , Antioxidants/analysis , Antioxidants/therapeutic use , Body Mass Index , Child , Cohort Studies , Cross-Sectional Studies , Cystic Fibrosis/diet therapy , Dietary Supplements/adverse effects , Exocrine Pancreatic Insufficiency/etiology , Female , Forced Expiratory Volume , Humans , Male , Odds Ratio , Oxidative Stress , Prospective Studies , Thinness/etiology , Vitamin A/adverse effects , Vitamin A/therapeutic use , Young AdultABSTRACT
This prospective study evaluated the effects of cisapride on corrected QT interval (QTc) in infants and children. From October 2000 to March 2003 two electrocardiograms (ECG) were obtained for 175 children (ranging in age from 1.5 months to 16.8 years), before and after 15 days of treatment with cisapride (0.2 mg/kg/dose, 3-4 times/day). A single posttreatment ECG was also obtained for 24 patients (ranging in age from 1.5 month to 15.8 years). No statistically significant differences were found between the mean QTc interval before (0.390 [0.018 s]) and after treatment (0.391 [0.018 s]). In patients for whom only a posttreatment ECG recording was performed, mean QTc interval was 0.399 (0.018 s). The QTc interval was never longer than 0.450 s in any of the children. In our experience the use of cisapride at therapeutic doses in infants and children who have no associated risk factors does not significantly prolong QTc interval.
Subject(s)
Cisapride/adverse effects , Electrocardiography/drug effects , Gastroesophageal Reflux/drug therapy , Gastrointestinal Agents/adverse effects , Long QT Syndrome/chemically induced , Adolescent , Age Distribution , Child , Child, Preschool , Female , Humans , Infant , Long QT Syndrome/diagnosis , Male , Prospective Studies , Statistics, Nonparametric , Treatment OutcomeABSTRACT
Se valoró de forma prospectiva el efecto en el intervalo QT corregido (QTc) del tratamiento con cisaprida en niños. Desde octubre de 2000 a marzo de 2003, se realizó un electrocardiograma (ECG) basal y otro a los 15 días de tratamiento con cisaprida (o,2 mg/kg/dosis, 3-4 veces/día) a 175 niños (edad entre 1, 5 meses y 15, 8 años). No se encontraron diferencias estadísticamente significativas entre el intervalo QTc medio basal (0, 390 +- 0, 018 s) y postratamiento (0, 391+-0,018 s). En los enfermos con un único ECG postratamineto, el intervalo QTc medio fue de 0, 399+-0,018 s. En ningún caso el intervalo QTc superó los 0,450 s. Según nuestra experiencia, la utilización de cisaprida en dosis terapéticas en niños sin factores de riesgo asociados no prolonga significativamente el intervalo QTc (AU)
